From Bench-to-Bedside: A Review of Clinical Trials in Drug Discovery and Development
Read the original on arXiv Computation and Language →The Flow has not summarised this story yet — read it at arXiv Computation and Language.
The Flow has not summarised this story yet — read it at arXiv Computation and Language.
arXiv:2609.21859v1 Announce Type: new Abstract: Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely o...
arXiv:2609.01202v1 Announce Type: cross Abstract: Clinical trials are essential for advancing cancer care and drug development, but many fail because of insufficient patient enrollment. While there i...
arXiv:2607. 02944v1 Announce Type: cross Abstract: We propose PRECEDE, a precedent-guided co-scientist for side-effect-aware drug redesign that revises a parent compound to mitigate a specified side effect while preserving therapeutic function.
arXiv:2511. 19735v2 Announce Type: replace-cross Abstract: Randomized controlled trials (RCTs)have been the cornerstone of clinical evidence; however, their cost, duration, and restrictive eligibility criteria limit power and external validity.
arXiv:2604. 14514v2 Announce Type: replace Abstract: Healthcare disparities persist across socioeconomic boundaries, often attributed to unequal access to screening, diagnostics, and therapeutics.
arXiv:2502. 18864v2 Announce Type: replace Abstract: Scientific discovery is driven by scientists generating novel hypotheses for complex problems that undergo rigorous experimental validation.